NIAID encourages Small Business applications in the areas of HIV/AIDS prevention and treatment as described in the table below.
The mission of Division of AIDS (DAIDS) is to help ensure an end to the HIV/AIDS epidemic by increasing basic knowledge of the pathogenesis and transmission of the human immunodeficiency virus (HIV); supporting the development of therapies for HIV infection and its complications and co-infections; and supporting the development of vaccines and other prevention strategies.
Below are areas of interest from DAIDS. The subject matter expert is available to answer questions and advise you on the application process.
If you do not see your HIV/AIDS-related topic here, the application may not be prioritized but will still be reviewed. Contact Brigitte Sanders if you have any questions about your application and don’t see an appropriate subject matter expert below.
| Areas of Interest | Subject Matter Experts |
|---|---|
| Preclinical research to assess and overcome specific biomedical obstacles in HIV vaccine discovery, especially by application of innovative technologies, and/or by the development and supply of novel reagents/resources useful for advancing original vaccine platforms. | Anjali Singh Preclinical Research and Development Branch |
|
Translational research to facilitate advancing novel promising basic SIV/HIV vaccine research concepts into HIV vaccine products, including: 1) vector optimization for expression, safety, and manufacturability; 2) upstream and downstream development activities; 3) analytics development to support in process testing and release; 4) formulation development; 5) novel adjuvant approaches; 6) GMP manufacturing; and 7) preclinical safety and toxicology modeling. |
Michael Pensiero |
|
Development of rapid diagnostic tests to distinguish HIV-vaccinated and HIV-infected individuals. HIV Env immunogens formulated with immunological adjuvant(s): Development of assays to ensure proper formulation, antigen/adjuvant integrity and potency, and characterization of immunological space post-vaccination. Evaluation and monitoring of vaccine safety and efficacy by identifying biomarkers of safety, autoimmunity, inflammation, and immunogenicity. |
Milton Maciel |
|
Preclinical development of single and combination non-vaccine biomedical prevention (nBP) candidates for sustained and extended release (SER) pre-exposure prophylaxis (PrEP) and multipurpose prevention technologies (MPT) candidates to prevent transmission of HIV in the genital and gastrointestinal tracts of men and women. Development of oral, injectable, implantable, and topical SER delivery strategies for PrEP and MPT. Development of new strategies for post-exposure prophylaxis (PEP). Creation and advancement of new technologies, targets, and approaches, including nanotechnology, which promote the safety, efficacy, adherence, and acceptability of non-vaccine biomedical prevention candidates and strategies. |
James Cummins |
|
Discovery and development of agents or strategies for PrEP (single or multiple agents, immunological, pharmacological, or other potential approaches directed against viral and/or host targets). Development of pharmacological tools to examine PK/PD in fluids and tissue, new formulation and delivery systems (including nanotechnology-based approaches) for coitally dissociated use, and optimization of animal models for screening of candidate agents. |
Adeola Adeyeye |
|
Development of novel assay for the determination of HIV incidence. These diagnostic assays should identify HIV incidence in the first year of infection, be based on B and non-B subtypes, differentiate those with early vs. chronic HIV infection and latent infection, and include the development, incorporation, and validation of process controls. Development of novel tools or modify existing approaches to monitor adherence and facilitate delivery of targeted interventions to improve adherence to ART, PrEP, and other HIV prevention interventions and strategies. |
Usha Sharma |
|
Development of formulation strategies to deliver antiretrovirals to specific target cells or tissues. Development of sustained release formulations to be delivered by oral, injectable, implantable, or transdermal routes of administration for treatment of HIV infection. |
Marina Protopopova |
|
Preclinical and clinical research to evaluate new or improved therapies for the treatment and prevention of HIV-related serious infectious and non-infectious complications in HIV-infected adults. Evaluation of therapeutic agents or diagnostics for hepatitis B or hepatitis C in HIV infected in adults. Development and delivery of nanotechnology-based therapeutics to target HIV-associated pathogen or pathogen-infected cells. |
Chris Lambros |
|
Small molecule inhibitors of viral and cellular targets not yet covered by FDA-approved antiretrovirals; HIV therapeutics discovery including high-throughput screening; development of nanotechnology-based therapeutics; HIV gene therapies, including vector design; animal models for HIV therapeutics and cure strategies. |
Brigitte Sanders |
|
HIV therapeutic vaccines, monoclonal antibody discovery and development for therapeutic use; immune-based HIV cure strategies; assays to measure the latent HIV reservoir. |
Tony Conley |
|
Development of novel methods for the diagnosis of active and latent TB infection in HIV-positive or HIV-negative infants and children. Development of prognostic biomarkers for risk of development of active TB and prediction of treatment response. Development of rapid testing for susceptibility of multiple antimycobacterial drugs for MTb from clinical samples. |
Richard Hafner |
|
Development and evaluation of practical and affordable tests to measure viral load, drug toxicities, and drug resistance to monitor populations in resource-poor settings. Development of tests to detect early infection in seropositive HIV-infected adult and pediatric individuals. |
Naana Cleland |
|
Development of rapid tests for the detection of ARTs in various human matrices (e.g., blood, urine, hair). The assay should require minimal operator effort and expertise, and include the development, incorporation, and validation of process controls. |
Keith Crawford |
Learn more about NIAID Small Business Programs.